Latest News

Mesoblast (ASX:MSB) has appointed experienced biotechnology and pharmaceutical finance executive James M. O’Brien as its new US-based Chief Financial Officer, marking a significant step in the company’s transition toward becoming a fully integrated commercial organisation.

Syntara (ASX:SNT) has achieved a significant regulatory milestone, announcing it has received a positive opinion from the European Medicines Agency on its application for Orphan Drug Designation for amsulostat (SNT-5505) in myelofibrosis.

Argent BioPharma (ASX:RGT) has taken a significant step toward its next phase of growth, securing a new $11 million financing facility from US-based venture fund C/M Capital to complete the acquisition of AusCann Group assets and accelerate commercial development plans.

Race Oncology (ASX:RAC) has announced a significant expansion of its clinical development strategy, unveiling two new programs for its lead asset, RC220, in acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer.

Noxopharm (ASX:NOX) has reached a new milestone in its development of SOF-SKN, announcing that the first dose has now been administered in Part Two of the HERACLES clinical trial.

Radiopharm Theranostics (ASX:RAD) has hit a significant milestone in its Phase 2b clinical trial evaluating RAD101, announcing that the study has now reached 50 per cent of its planned patient enrollment.

Recce Pharmaceuticals (ASX:RCE) has announced the passing of its founder, Dr Graham JH Melrose, a distinguished scientist, inventor and long-time champion of innovative anti-infective technologies.

Biotron (ASX:BIT) has released new data demonstrating significant progress in its Hepatitis B Virus development program, with its lead candidate BIT-HBV001 showing potent antiviral effects across multiple laboratory and animal models.

PYC Therapeutics (ASX:PYC) has reported encouraging long-term data from its ongoing Phase 1/2 clinical program for VP-001, an investigational treatment targeting Retinitis Pigmentosa type 11.

Australia’s vaccine and infectious-disease research sector has received a significant boost with the official launch of Biointelect Venturer, a new national incubator designed to accelerate local scientific breakthroughs from early discovery toward commercial reality.

The study, which is evaluating the company’s immunotherapy eftilagimod alfa in combination with radiotherapy and MSD's KEYTRUDA (pembrolizumab) for resectable soft tissue sarcoma, significantly exceeded its prespecified pathologic response target.

PYC Therapeutics (ASX:PYC) has announced a significant step in its board renewal process, appointing former Woodside chief executive Peter Coleman as its new Independent Non-Executive Chair, effective immediately after the company’s Annual General Meeting on 18 November 2025.